HeartSciences Inc. cash flow to debt ratio of -0.19% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

HeartSciences Inc.'s free cash flow has decreased 20.59% from $-6.20M last year to $-7.47M, signaling decreasing performance

HeartSciences Inc.'s debt to equity ratio is -1.97, signaling that the company spent its equity and risk bankruptcy.

HeartSciences Inc.'s debt has increased relative to shareholder equity from 14.55 last year to -1.97 today, signaling weakened financials

HeartSciences Inc. has negative EBITDA, making leverage ratio unreliable

HeartSciences Inc.'s interest coverage ratio is -11.78, which means that the company struggles to meet interest obligations, signaling financial risk.

HeartSciences Inc.'s profit margin was -201.50K% last year and is -227.02K% this year, signaling decreasing performance

HeartSciences Inc.'s short-term liabilities of $4.86B exceed its short-term assets of $2.58B, signaling financial risk

HeartSciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

HeartSciences Inc.'s return on equity of -816.25%, is lower than 15.00%, indicating bad performance

HeartSciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

HeartSciences Inc. has insufficient public price history to evaluate earnings stability.

HeartSciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

HeartSciences Inc. has negative free cash flow, indicating cash burn

HeartSciences Inc.'s yearly earnings has decreased 4.30% since last year from $-8.77M to $-9.14M, signaling decreasing performance

HeartSciences Inc.'s yearly revenue has decreased 76.61% since last year from $18.60K to $4.35K, signaling decreasing performance

ROIC -480.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

HeartSciences Inc.'s 3-year revenue CAGR of -5.70% is negative, indicating declining revenue over the past 3 years

HeartSciences Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

HeartSciences Inc. has insufficient public price history to evaluate ROE consistency.

HeartSciences Inc. has insufficient data to evaluate this check.

HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HeartSciences Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

HeartSciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

HeartSciences Inc. has insufficient data to evaluate this check.

HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HeartSciences Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

HeartSciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue